What data suggests that statins are beneficial in patients with a functioning kidney transplant?
Data from the placebo arm of the ALERT trial suggests that the rate of cardiovascular death or non-fatal MI is approximately 21.5 per 1000 patient-years. Data from a population-based study from Australia and New Zealand suggests that the rate of cardiovascular death alone is approximately 5 per 1000 patient-years even among those aged 25-44 years. Fluvastatin therapy led to a non-significant 17% reduction in the primary outcome of coronary death or non-fatal MI, compared to placebo. An unblinded extension study found that randomization to fluvastatin was associated with a significant reduction in the original primary outcome after 6.7 years of follow-up.